Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer

Cancer Letters

Volumn 302, Issue 2, 2011, Pages 155-165

  Nam, Hyun Jin ^a   Kim, Hwang Phill ^a   Yoon, Young Kwang ^a   Hur, Hyung Seok ^a   Song, Sang Hyun ^a   Kim, Maeng Sup ^d   Lee, Gwan Sun ^d   Han, Sae Won ^a,b   Im, Seock Ah ^a,b   Kim, Tae You ^a,b,c   Oh, Do Youn ^a,b   Bang, Yung Jue ^a,b,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University   (South Korea)

^d Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

Antitumor activity; Chemotherapeutic agents; Gastric cancer; HM781 36B; Pan HER inhibitor

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AFATINIB; ANTINEOPLASTIC AGENT; CANERTINIB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEFITINIB; HM 781 36B; LAPATINIB; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN; CELL STRAIN N87; CELL STRAIN SNU216; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 79951580512     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.010     Document Type: Article

References (42)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
2. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
3. King C.R., Borrello I., Bellot F., Comoglio P., Schlessinger J. Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J. 1988, 7:1647-1651.
4. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1:1311-1318.
5. Kim S.Y., Kim H.P., Kim Y.J., Oh do Y., Im S.A., Lee D., Jong H.S., Kim T.Y., Bang Y.J. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int. J. Oncol. 2008, 32:89-95.
6. Hirata A., Hosoi F., Miyagawa M., Ueda S., Naito S., Fujii T., Kuwano M., Ono M. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res. 2005, 65:4253-4260.
7. Piechocki M.P., Yoo G.H., Dibbley S.K., Lonardo F. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Res. 2007, 67:6825-6843.
8. Kim J.W., Kim H.P., Im S.A., Kang S., Hur H.S., Yoon Y.K., Oh D.Y., Kim J.H., Lee D.S., Kim T.Y., Bang Y.J. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2008.
9. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., Untch M., Rusnak D.W., Spehar G., Mullin R.J., Keith B.R., Gilmer T.M., Berger M., Podratz K.C., Slamon D.J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66:1630-1639.
10. Kim H.P., Han S.W., Kim S.H., Im S.A., Oh D.Y., Bang Y.J., Kim T.Y. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther. 2008, 7:607-615.
11. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., Gilmer T.M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1:85-94.
12. Kim H.P., Yoon Y.K., Kim J.W., Han S.W., Hur H.S., Park J., Lee J.H., Oh D.Y., Im S.A., Bang Y.J., Kim T.Y. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS ONE 2009, 4:e5933.
13. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 2005, 352:786-792.
14. Kobayashi S., Ji H., Yuza Y., Meyerson M., Wong K.K., Tenen D.G., Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005, 65:7096-7101.
15. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., Zhao F., Vincent P.W., Naumov G.N., Bradner J.E., Althaus I.W., Gandhi L., Shapiro G.I., Nelson J.M., Heymach J.V., Meyerson M., Wong K.K., Janne P.A. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007, 67:11924-11932.
16. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
17. de La Motte Rouge T., Galluzzi L., Olaussen K.A., Zermati Y., Tasdemir E., Robert T., Ripoche H., Lazar V., Dessen P., Harper F., Pierron G., Pinna G., Araujo N., Harel-Belan A., Armand J.P., Wong T.W., Soria J.C., Kroemer G. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007, 67:6253-6262.
18. Wong T.W., Lee F.Y., Yu C., Luo F.R., Oppenheimer S., Zhang H., Smykla R.A., Mastalerz H., Fink B.E., Hunt J.T., Gavai A.V., Vite G.D. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin. Cancer Res. 2006, 12:6186-6193.
19. Emanuel S.L., Hughes T.V., Adams M., Rugg C.A., Fuentes-Pesquera A., Connolly P.J., Pandey N., Moreno-Mazza S., Butler J., Borowski V., Middleton S.A., Gruninger R.H., Story J.R., Napier C., Hollister B., Greenberger L.M. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol. Pharmacol. 2008, 73:338-348.
20. Ku J.L., Park J.G. Biology of SNU cell lines. Cancer Res. Treat. 2005, 37:1-19.
21. Fujimoto-Ouchi K., Sekiguchi F., Yasuno H., Moriya Y., Mori K., Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother. Pharmacol. 2007, 59:795-805.
22. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
23. Erlichman C., Boerner S.A., Hallgren C.G., Spieker R., Wang X.Y., James C.D., Scheffer G.L., Maliepaard M., Ross D.D., Bible K.C., Kaufmann S.H. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001, 61:739-748.
24. Lee K.W., Kim J.H., Park J.H., Kim H.P., Song S.H., Kim S.G., Kim T.Y., Jong H.S., Jung K.H., Im S.A., Kim T.Y., Kim N.K., Bang Y.J. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res. 2006, 26:3429-3438.
25. Yoon Y.K., Kim H.P., Han S.W., Hur H.S., Oh Y., Im S.A., Bang Y.J., Kim T.Y. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 2009, 8:2526-2536.
26. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
27. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
28. Tanner M., Hollmen M., Junttila T.T., Kapanen A.I., Tommola S., Soini Y., Helin H., Salo J., Joensuu H., Sihvo E., Elenius K., Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005, 16:273-278.
29. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S.D., Stein S., Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl. J. Med. 2006, 355:2733-2743.
30. J. León-Chong, F. Lordick, Y.K. Kang, S.R. Park, Y.J. Bang, A. Sawaki, E. Van Cutsem, O. Stoss, B.W. Jordan, A. Feyereislova, HER2 positivity in advanced gastric cancer is comparable to breast cancer. ASCO Annual Meeting Proceedings 2007, J. Clin. Oncol. 25 (18S) (2007) Abstract 15057.
31. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005, 23:2445-2459.
32. Soltoff S.P., Carraway K.L., Prigent S.A., Gullick W.G., Cantley L.C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 1994, 14:3550-3558.
33. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
34. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Ruschoff J., Kang Y.K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
35. Gong Y., Somwar R., Politi K., Balak M., Chmielecki J., Jiang X., Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 2007, 4:e294.
36. Costa D.B., Halmos B., Kumar A., Schumer S.T., Huberman M.S., Boggon T.J., Tenen D.G., Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007, 4:1669-1679. (discussion 1680).
37. Lee K.H., Hur H.S., Im S.A., Lee J., Kim H.P., Yoon Y.K., Han S.W., Song S.H., Oh D.Y., Kim T.Y., Bang Y.J. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett. 2010, 299:22-28.
38. Okabe T., Okamoto I., Tsukioka S., Uchida J., Hatashita E., Yamada Y., Yoshida T., Nishio K., Fukuoka M., Janne P.A., Nakagawa K. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin. Cancer Res. 2009, 15:907-913.
39. Li X.D., Geng Y.T., Wu C.P., Shen H., Sun J., Shu Y.Q., Yin Y.M. Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer. Onkologie 2010, 33:466-469.
40. Cole C., Lau S., Backen A., Clamp A., Rushton G., Dive C., Hodgkinson C., McVey R., Kitchener H., Jayson G.C. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol. Ther. 2010, 10:495-504.
41. Pietras R.J., Poen J.C., Gallardo D., Wongvipat P.N., Lee H.J., Slamon D.J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999, 59:1347-1355.
42. Osawa K. Gene Polymorphisms and chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009, 12:837-840.